id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-E-1232-0008,FDA,FDA-2012-E-1232,Letter from U.S. Patent and Trademark Office to Covington & Burling LLP,Other,Letter(s),2024-04-10T04:00:00Z,2024,4,2024-04-10T04:00:00Z,,2024-04-10T16:05:50Z,,0,0,09000064864c1100
FDA-2012-E-1232-0007,FDA,FDA-2012-E-1232,Order to Show Cause from U.S. Patent and Trademark Office to Covington & Burlington LLP,Other,Order,2024-02-20T05:00:00Z,2024,2,2024-02-20T05:00:00Z,,2024-02-20T21:27:28Z,,0,0,09000064863cf142
FDA-2012-E-1232-0006,FDA,FDA-2012-E-1232,Determination of Regulatory Review Period for Purposes of Patent Extension; BELVIQ,Other,Letter(s),2017-03-10T05:00:00Z,2017,3,2017-03-10T05:00:00Z,,2017-03-10T16:15:49Z,,0,0,09000064824ffecc
FDA-2012-E-1232-0005,FDA,FDA-2012-E-1232,"Determination of Regulatory Review Period for Purposes of Patent
Extension; BELVIQ",Notice,Determinations,2016-09-23T04:00:00Z,2016,9,2016-09-23T04:00:00Z,2016-11-23T04:59:59Z,2024-04-08T18:16:30Z,2016-22937,0,0,090000648225c3bc
FDA-2012-E-1232-0004,FDA,FDA-2012-E-1232,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-18T04:00:00Z,2016,8,2016-08-18T04:00:00Z,,2016-08-18T13:02:29Z,,0,0,0900006482180738
FDA-2012-E-1232-0003,FDA,FDA-2012-E-1232,Letter to U. S..Patent & Trademark Office,Other,Letter(s),2013-02-14T05:00:00Z,2013,2,2013-02-14T05:00:00Z,,2024-03-15T11:06:43Z,,0,0,09000064811f897f
FDA-2012-E-1232-0002,FDA,FDA-2012-E-1232,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T23:56:54Z,,0,0,090000648119ce89
FDA-2012-E-1232-0001,FDA,FDA-2012-E-1232,"Arena Pharmaceuticals, Inc. (Finnegan Henderson LLP) - Patent Extension Application",Other,Application,2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T23:56:33Z,,0,0,090000648119ce87